CAPRICOR THERAPEUTICS, INC. (CAPR) intrinsic value & 10-year financials
CAPRICOR THERAPEUTICS, INC. (CAPR) has a Graham intrinsic value of $0.75 per share. At $6.71 on Oct 17, 2026, the stock trades 795% above that value. Over the last 10 fiscal years revenue grew 23.9% a year to $0, with an average return on invested capital of 44.7%.
- Graham intrinsic value
- $0.75
- Share price (Oct 17, 2026)
- $6.71
- Price vs Graham value
- 795% above
- Market cap
- $311.9M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 23.9%
- ROIC (10-yr avg)
- 44.7%
- Free cash flow (FY2025)
- -$72.7M
CAPR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$105.0M | -$2.26 | -$72.7M | — | -129.5% |
| FY2024 | $22.3M | -$40.5M | -$1.15 | -$41.2M | -191.1% | -59.0% |
| FY2023 | $25.2M | -$22.3M | -$0.83 | -$26.9M | -95.6% | -331.3% |
| FY2022 | $2.6M | -$29.0M | -$1.18 | $2.9M | -1142.2% | -1937.0% |
| FY2021 | $244.9K | -$20.0M | -$0.87 | -$18.0M | -8549.9% | 768.2% |
| FY2020 | $310.2K | -$13.7M | -$0.88 | -$10.6M | -4412.6% | 2261.3% |
| FY2019 | $1.0M | -$7.6M | — | — | -769.5% | -259.9% |
| FY2018 | $1.7M | -$15.2M | -$0.13 | -$14.2M | -917.0% | — |
| FY2017 | $2.7M | $2.4M | $0.02 | -$14.3M | -482.4% | — |
| FY2016 | $4.0M | -$18.8M | -$0.25 | -$14.6M | -424.6% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CAPRICOR THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CAPRICOR THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -26.2% ROIC.
Over the decade, CAPRICOR THERAPEUTICS, INC. shows that management has aggressively returned capital to shareholders by retiring 37.4% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CAPRICOR THERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.75 per share.